Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
Neal Shore, MD, FACS, offers clinical insights on optimizing patient selection and treatment sequencing in BCG-unresponsive NMIBC.
EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC
EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
EP: 4.Ongoing Research in BCG-Unresponsive NMIBC
EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
EP: 6.Emerging Agents in BCG-Unresponsive NMIBC
EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
In concluding remarks on optimizing care, Shore reinforces that BCG remains standard of care for initial treatment of high-risk non–muscle invasive bladder cancer when available. In shortage settings, alternatives like dose-dense gemcitabine plus docetaxel should be considered. Across settings, enrolling patients in clinical trials is critical to advance the field.
For BCG-unresponsive patients, Shore recommends urologic oncologists consider checkpoint inhibitor immunotherapy if comfortable with managing potential immune-related adverse events. Collaboration with medical oncologists is advised given their expertise with these agents. Preventing recurrence and progression remains central to improving patient outcomes and burden of intensive management. Ultimately, Shore conveys excitement for preventing disease advancement in bladder cancer through new therapeutic strategies.
Video synopsis is AI generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
